HOME >> BIOLOGY >> NEWS
First clinical trial of gene therapy for muscular dystrophy now under way

MDA) awarded $1.6 million to AskBio to develop gene therapy strategies for DMD.

Rounding out the AskBio team clinically is neurologist Dr. Jerry R. Mendell, co-director of the MDA clinic at Columbus Children's Hospital; professor of pediatrics, neurology and pathology at Ohio State University's School of Medicine; and head of the neuromuscular research program and Center for Gene Therapy at Columbus Children's Research Institute. In the clinical trial at the Columbus Children's Hospital's MDA clinic, Mendell will administer the injections.

Following extensive laboratory toxicity experiments required by the U.S. Food and Drug Administration demonstrating that minidystrophin gene transfer was unlikely to harm and could ultimately benefit muscles affected by DMD, approval was granted March 3, 2006, to proceed with the human trial.

"After years of encouraging pre-clinical results, I'm excited that AskBio will help bring this promising new therapy into the clinic, and look forward with a great deal of optimism to offering this initial step toward hope for the DMD community," Samulski said.


'"/>

Contact: Stephanie Crayton
scrayton@unch.unc.edu
919-966-2860
University of North Carolina at Chapel Hill
29-Mar-2006


Page: 1 2 3 4

Related biology news :

1. First case of successful ovarian tissue transplantation between two, nonidentical sisters
2. First new multiple sclerosis gene found in 30 years
3. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
4. First all-African produced genetically engineered maize is resistant to maize streak virus
5. First baby is born after oocytes were matured in the lab and frozen
6. First confirmed common genetic risk factors for breast cancer
7. First demonstration of new hair follicle generation in an animal model
8. First research to show that diabetes damages DNA in mens sperm and may affect fertility
9. First demonstration of muscle restoration in an animal model of Duchenne muscular dystrophy
10. First systematic study of Chinas one-child policy reveals complexity, effectiveness
11. First international conference on self-healing materials

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First clinical trial gene therapy for muscular dystrophy now under way

(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
(Date:4/23/2015)... April 23, 2015  Metanome, Inc., an industry ... company has changed its name to Diversigen, Inc.  ... as the single commercial source for the myriad ... on the diverse opportunities of the microbiome.  From ... accepts – including those that are difficult to ...
(Date:4/23/2015)... 2015 /PRNewswire/ - Crystal Research Associates, LLC announced today ... (EIO) on Aeterna Zentaris Inc. (NASDAQ: AEZS ... Crystal Research Associates, website at www.crystalra.com ... www.aezsinc.com . Aeterna Zentaris ("Aeterna" or ... in oncology, endocrinology, and women,s health. With a focus ...
(Date:4/23/2015)... 23, 2015 Delpor, Inc. (Delpor), a ... the United States Patent and Trademark Office has issued ... technology. US Pat. No. 8,986,727 was issued ... drug delivery device for the sustained release of ... for the sustained (zero-order) release of large and small ...
(Date:4/22/2015)... 22, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... and accomplishments. For the first quarter ended ... of $5.3 million, or $0.08 per share, compared to ... share, for the same period in 2014. As of ... marketable securities and interest receivable of $226.1 million. ...
Breaking Biology Technology:Metanome Announces Corporate Name Change to Diversigen 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8
Cached News: